CRISPR Therapeutics AG (NASDAQ: CRSP) is a clinical-stage biopharmaceutical company incorporated in Switzerland that develops gene-based medicines using CRISPR/Cas9 and related technologies. The company generates revenue through collaboration agreements, milestone payments, and royalties from partners, most notably Vertex Pharmaceuticals, rather than from broad commercial product sales. Its first approved product, CASGEVY (exagamglogene autotemcel), is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for hemoglobinopathies and represents the first CRISPR-based therapy to receive regulatory approval. The pipeline spans ex vivo CAR-T oncology programs, in vivo liver-targeted programs using lipid nanoparticle delivery (including cardiovascular candidates CTX310 and CTX340), siRNA-based cardiovascular programs developed with Sirius, and a regenerative medicine program in Type 1 diabetes (CTX213). CRSP has reported significant operating losses since inception and does not pay a dividend. The company is headquartered in Switzerland and files as a foreign private issuer on U.S. exchanges.

Revenue model

Collaboration agreements, milestone payments, and royalties from strategic partners, primarily Vertex Pharmaceuticals. Commercial revenue from CASGEVY is shared under the Vertex collaboration. No broad independent product revenue stream is disclosed in the filing excerpts.

Products and services

CASGEVY (exagamglogene autotemcel), an approved ex vivo CRISPR/Cas9 cell therapy for hemoglobinopathies. Pipeline includes: zugocabtagene geleucel and additional CAR-T oncology candidates; CTX310 (ANGPTL3, Phase 1b) and CTX340 (angiotensinogen) in cardiovascular in vivo programs; CTX321 (LPA) and CTX460 (SERPINA1/alpha-1 antitrypsin deficiency) using the proprietary SyNTase platform; siRNA-based cardiovascular and thromboembolic programs with Sirius; CTX213 (beta cell replacement for Type 1 diabetes).

Customers and end markets

Patients with rare and common diseases including sickle cell disease, beta-thalassemia, hematologic cancers, cardiovascular disease, refractory hypertension, alpha-1 antitrypsin deficiency, and Type 1 diabetes. Commercial and clinical partners, primarily Vertex Pharmaceuticals, are the direct revenue counterparties.

Value-chain role

Drug discovery, gene editing platform development, clinical-stage development, and co-commercialization through partnerships. Relies on third-party manufacturers for gene editing and cell therapy production.

Geographic exposure

Incorporated in Switzerland; subject to FDA (United States), MHRA (United Kingdom), and EMA (European Union) regulatory oversight. Specific revenue geographic breakdown not disclosed in filing excerpts.

Source: SEC 10-K, filed 2026-02-12

Industry: Biological Products, (No Diagnostic Substances) Peers: AC Immune SA ADC Therapeutics SA VectivBio Holding AG